JFL Life NSE SME RI review - (Not Rated)

•    The company is engaged in the pharma/healthcare segment.
•    It has expanded its product portfolio from antibiotics to general remedies.
•    The company has posted average growth for the reported periods.
•    Based on its recent financial data, the issue appears fully priced.
•    Well-informed/cash surplus investors may park moderate funds for medium term.

ABOUT COMPANY:
JFL Life Sciences Ltd., (JLSL) originally incorporated as ‘JFL Life Sciences Private Limited’ on April 25, 2010, embarked on its journey as a private limited entity with a clear vision of becoming a key player in the pharmaceutical industry. The company’s foundation was built upon the deep industry knowledge and expertise of its promoters, which allowed it to swiftly navigate the complexities of the sector. By 2013, it had successfully commenced commercial production, establishing JLSL’s operational prowess and laying the groundwork for future growth.

This marked an important milestone in its journey, as the company began to leverage capabilities to cater to the growing demands of the healthcare sector. In 2015, JLSL made a strategic move to expand its product portfolio by venturing into the manufacturing of Beta-Lactam tablets and capsules, focusing primarily on antibiotic drugs. This was a significant expansion that aligned with the growing global demand for antibiotics. As part of this growth strategy, it quickly followed up with the manufacturing of Beta-Lactam injectables, further broadening its range of antibiotic solutions. These developments not only expanded its product offerings but also positioned it as a key player in the antibiotic segment, catering to both domestic and international markets.

Continuing with its momentum, in 2017, the company further diversified by entering the manufacturing of general tablets and capsules. Its product line grew to include crucial formulations such as anti-inflammatory, antigastric, and painkiller medications, reflecting its commitment to addressing a broader spectrum of healthcare needs. This diversification not only enhanced its market reach but also demonstrated capability to adapt to changing market dynamics and customer demands.

In 2020, recognizing the need to scale up its operations and meet growing market demands, it made a significant investment by acquiring a new manufacturing facility. This state-of-the-art plant, dedicated solely to the production of general tablets and capsules, has enabled it to increase production capacity, improve efficiency, and maintain the highest standards of quality. This acquisition represents a critical step in its long term strategy to strengthen infrastructure and remain competitive in an evolving pharmaceutical landscape. 

Throughout this journey, JLSL has remained focused on innovation, quality, and a commitment to excellence, ensuring that it continues to meet the needs of customers while contributing to the advancement of global healthcare. Currently, the company operates in the manufacturing of pharmaceutical products, with a presence across India and in 10 developed and developing countries, it is committed to advancing healthcare through a strong Quality Check foundation and an FDA-approved, state-of-the-art manufacturing facility near Ahmedabad, Gujarat.

The company operates as a manufacturing company with a bulk sales strategy, supplying products to pharmaceutical marketers and traders who handle the distribution channels. This approach applies to both its domestic and international markets, and it does not sell products under any brand name. In recent developments, it has started selling of pharmaceutical products on its own brand name as a manufacturer in the domestic market mainly in Gujarat. It is also formulator supplier to the “Rajasthan Government” since 2024. As of March 31, 2025, it had 17 employees on its payroll. The company has pending litigations worth Rs. 22.88 cr. that raises alarm.

ISSUE DETAILS:
The company is coming out with its Rights Issue (RI) of 32995323 equity shares of Rs. 10 each at par value to mobilize Rs. 33.00 cr. The RI opens for subscription on March 16, 2026, and will close on March 24, 2026. The company is offering RI in the ratio of 1 for 1 to its eligible stakeholders as of the record date of March 10, 2026. The company is asking for full money on application for number of shares applied. Post allotment, RI shares will be listed on NSE SME. The company is spending Rs. 1.00 cr. for this RI process, and from the net proceeds, it will utilize Rs. 9.52 cr. for construction of new manufacturing plant, Rs. 5.52 cr. for installation of machinery, Rs. 13.45 cr. for working capital, and Rs. 3.51 cr. for general corporate purposes. The market lot for this counter is 6000 shares.

The RI is solely lead managed by the company itself., and KFin Technologies Ltd. is the registrar to the issue. 

Post-RI, company’s current paid-up equity capital of Rs. 33.00 cr. will stand enhanced to Rs. 65.99 cr. Based on the RI pricing, the company is looking for a market cap of Rs. 65.99 cr. 

FINANCIAL PERFORMANCE:
On the financial performance front, for the last two fiscals, the company has (on a consolidated basis) posted total income / net profit, of Rs. 47.06 cr. / Rs. 3.30 cr. (FY24), Rs. 82.05 cr. / Rs. 4.16 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it posted a net profit of Rs. 4.69 cr. on a total income of Rs. 68.36 cr. 

DIVIDEND POLICY:
The company paid a dividend of 2.5% in September 2024. It will adopt a prudent dividend policy, based on its financial performance and future prospects. The offer document is silent on its dividend policy.

SCRIP PERFORMANCE: BASED ON NSE WEBSITE DATA: SCRIP CODE: JFLLIFE (FV Rs. 10).
The scrip last closed on cum-right basis at Rs. 11.00 on March 09, 2026, and opened on an ex-right basis at Rs. 10.75 on March 11, 2026. Since then, it has marked a high/low of Rs. 10.75 / Rs. 10.25. The scrip last closed at Rs. 10.25 as of March 13, 2026. For the last 52 weeks’ it has posted a high/low of Rs. 21.14 / Rs. 9.52. 

The promoters’ holding has been constant at 67.47% for the last three quarters ended on December 31, 2025. The counter is currently well managed by vested interests and trades marginally above the RI price, to tempt investors.